Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds Under Its SciSparc Ltd Collaboration
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds Under Its SciSparc Ltd Collaboration
Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has submitted three patent applications under the international Patent Cooperation Treaty ("PCT"), as part of its ongoing collaboration with SciSparc Ltd. (NASDAQ:SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
Clearmind Medicine Inc.（纳斯达克证券交易所代码：CMND）（FSE：CWY）（“Clearmind” 或 “公司”）是一家生物技术公司，专注于发现和开发新型迷幻药衍生疗法以解决治疗不足的重大健康问题。该公司今天宣布，它已根据《国际专利合作条约》（“PCT”）提交了三项专利申请，这是其与ScisPARC Ltd（纳斯达克）持续合作的一部分。Q: SPRC)（“ScisPARC”），一家处于临床阶段的专业制药公司，专注于开发治疗中枢神经疾病的疗法系统。